Studies on Parasitologic and Haematologic Activities of an Enaminone Derivative of 4-Hydroxyquinolin-2(1H)-one Against Murine Schistosomiasis Mansoni

Amal M. El–Shennawy, MD; Amira H. Mohamed, MD; Mohamed Abass, MD

In This Article


In addition to the favorable safety profile of BDHQ, its activity against schistosomes was recorded over a reasonably wide range of the life cycle since reductions in mean number of ova, immature stages and worm burden were enhanced especially in those treated with a high dose (20 mg x 2) of BDHQ. Its underlying mechanism(s) may be due to a direct assault on the tegument and the genital systems of male and female worms, as detected by electron microscopy, in addition to its role in immunologic mechanisms with mixed cellular and humoral responses, as detected by the significant increase in serum levels of IgE and IFN–gamma (as a result of remarkable cellular activation) on electron microscopy.

These results encourage us and emphasize the need to conduct additional clinical studies of this new drug in different epidemiologic settings and at higher doses. Future trials are needed to attempt to eradicate the immature form completely and to study the effect of BDHQ on Schistosoma hematobium.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: